Beyond the Batch podcast

The Project You Should Have Stopped a Year Ago

0:00
30:03
Rewind 15 seconds
Fast Forward 15 seconds

Many projects fail or hit roadblocks. 

But the moment a project "fails"  usually comes too late, rather than much earlier when someone on the team knew failure to be a likely outcome.

Phil Ramsey and Tiffany Rau dig into why struggling R&D and development projects keep getting funded, how to tell when to stop or regroup, and why gap analyses save years of work.

In this episode:

  • Why a program that delivered zero commercial successes still got its leader promoted, and what that says about culture
  • Development reasons to stop or regroup: the wrong expression system, a CDMO platform that doesn't fit the molecule, or a pipeline that has moved on
  • Why stopping development isn't the same as failure
  • What success means at each stage, from the target product profile and QTPP to process variability you can't control
  • Three kinds of development projects (variant, derivative, breakthrough), and why breakthroughs need stopping criteria on day one
  • Treating data as inventory: findable, consistently named, and documented with its context
  • What tighter venture funding forces small teams to do, and when an aggressive timeline becomes a silly one
  • The gap analysis that would have caught a product the plant could never make

Chapters:

  • 00:00 Intro
  • 00:23 Projects that should have been stopped
  • 03:39 Development reasons to stop or regroup
  • 05:17 Regrouping isn't failure
  • 06:44 What success means from discovery to scale-up
  • 09:49 Three kinds of development projects
  • 12:31 Keeping data you can find and trust
  • 15:52 Designed experiments and prediction
  • 20:20 Funding pressure on small teams
  • 23:29 What to do this week if your project is in trouble
  • 26:09 Gap analysis and the chemistry nobody could make

Hosts:

  • Nathaniel Leies, host
  • Philip Ramsey, Ph.D., Emeritus Professor of Statistics, University of New Hampshire; Vice President of Data Science and Analytics, Predictum Inc.
  • Tiffany Rau, Ph.D., Owner, Rau Consulting; global biotech and pharmaceutical consultant across the drug development lifecycle

Mentioned: 

  • Beyond the Batch Ep. 2 on uncertainty
  • CoBaseKRM, an application for capturing knowledge from scientific and engineering modeling, produced by Predictum: https://cobasekrm.com

Contact: Send questions or a voice recording to [email protected]. More at beyondthebatch.io.

Produced by Predictum Inc., in partnership with Rau Consulting.

More episodes from "Beyond the Batch"